Research progress on the mechanism of SGLT2 inhibitors in the treatment of inflammatory bowel disease
Inflammatory bowel disease(IBD)is a chronic inflammatory disease of intestinal tract with an elusive etiology.Its clinical course is influenced by a large variety of environmental,genetic,immunologic and microbiologic factors.Currently IBD has outstanding problems of high expenses,many adverse reactions from long-term use of therapeutic drugs and treatment intoler-ance.There is an urgent need for formulating novel therapeutic options.Recent studies have demonstrated that hypoglycemic agent sodium-glucose cotransporter-2 inhibitor(SGLT2i)could delay the progression of IBD through glucose-dependent and inde-pendent pathways.It was capable of attenuating inflammatory responses,ameliorating innate immune responses,antagonizing oxi-dative stress,arresting apoptosis,enhancing autophagy induction and regulating intestinal microbiota imbalance in IBD.
NETL
NSTL
万方数据
